It is notable that DLG5 expression is down‐regulated in CD44+/CD24− BCSCs.11 Our previous study and those of others have revealed that DLG5 silencing promotes the process of epithelial‐to‐mesenchymal transition (EMT) and stemness of ER+ breast cancer cells by inhibiting the Hippo signalling.5, 10, 12 However, how DLG5 regulates the stemness of breast cancer cells and TAM resistance has not been clarified. Here, CD44 is linked to breast carcinoma.